ID   CUL5_HUMAN              Reviewed;         780 AA.
AC   Q93034; A8K960; O14766; Q9BZC6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   28-JUN-2023, entry version 201.
DE   RecName: Full=Cullin-5 {ECO:0000305};
DE            Short=CUL-5 {ECO:0000305};
DE   AltName: Full=Vasopressin-activated calcium-mobilizing receptor 1 {ECO:0000303|PubMed:9037604};
DE            Short=VACM-1 {ECO:0000303|PubMed:9037604};
GN   Name=CUL5 {ECO:0000303|PubMed:10230407, ECO:0000312|HGNC:HGNC:2556};
GN   Synonyms=VACM1 {ECO:0000303|PubMed:9037604};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=9037604; DOI=10.1101/gr.7.1.71;
RA   Byrd P.J., Stankovic T., McConville C.M., Smith A.D., Cooper P.R.,
RA   Taylor A.M.R.;
RT   "Identification and analysis of expression of human VACM-1, a cullin gene
RT   family member located on chromosome 11q22-23.";
RL   Genome Res. 7:71-75(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Longo K.A., North W.G., Du J., Fay M.J.;
RL   Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RA   Kanaya K., Kamitani T.;
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH RBX1 AND RNF7.
RX   PubMed=10230407; DOI=10.1016/s1097-2765(00)80482-7;
RA   Ohta T., Michel J.J., Schottelius A.J., Xiong Y.;
RT   "ROC1, a homolog of APC11, represents a family of cullin partners with an
RT   associated ubiquitin ligase activity.";
RL   Mol. Cell 3:535-541(1999).
RN   [8]
RP   NEDDYLATION.
RX   PubMed=10597293; DOI=10.1038/sj.onc.1203093;
RA   Hori T., Osaka F., Chiba T., Miyamoto C., Okabayashi K., Shimbara N.,
RA   Kato S., Tanaka K.;
RT   "Covalent modification of all members of human cullin family proteins by
RT   NEDD8.";
RL   Oncogene 18:6829-6834(1999).
RN   [9]
RP   FUNCTION, IDENTIFICATION IN E3 UBIQUITIN-PROTEIN LIGASE COMPLEX WITH
RP   LRRC41, IDENTIFICATION IN A COMPLEX WITH ELOA, IDENTIFICATION IN A COMPLEX
RP   WITH SOCS1, AND IDENTIFICATION IN A COMPLEX WITH WSB1.
RX   PubMed=11384984; DOI=10.1074/jbc.m103093200;
RA   Kamura T., Burian D., Yan Q., Schmidt S.L., Lane W.S., Querido E.,
RA   Branton P.E., Shilatifard A., Conaway R.C., Conaway J.W.;
RT   "Muf1, a novel elongin BC-interacting leucine-rich repeat protein that can
RT   assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase.";
RL   J. Biol. Chem. 276:29748-29753(2001).
RN   [10]
RP   FUNCTION (MICROBIAL INFECTION), IDENTIFICATION IN COMPLEX WITH HUMAN
RP   ADENOVIRUS 5 PROTEINS E1B-55K AND E4-ORF6 (MICROBIAL INFECTION), AND
RP   NEDDYLATION.
RX   PubMed=12186903; DOI=10.1128/jvi.76.18.9194-9206.2002;
RA   Harada J.N., Shevchenko A., Shevchenko A., Pallas D.C., Berk A.J.;
RT   "Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to
RT   ubiquitination machinery.";
RL   J. Virol. 76:9194-9206(2002).
RN   [11]
RP   INTERACTION WITH HIV-1 VIF (MICROBIAL INFECTION).
RX   PubMed=15574592; DOI=10.1101/gad.1249904;
RA   Mehle A., Goncalves J., Santa-Marta M., McPike M., Gabuzda D.;
RT   "Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-
RT   Cul5 complex that promotes APOBEC3G degradation.";
RL   Genes Dev. 18:2861-2866(2004).
RN   [12]
RP   FUNCTION, IDENTIFICATION IN THE ECS(LRRC41) COMPLEX, IDENTIFICATION IN THE
RP   ECS(SOCS3) COMPLEX, IDENTIFICATION IN THE ECS(SPSB1) COMPLEX,
RP   IDENTIFICATION IN THE ECS(SPSB2) COMPLEX, IDENTIFICATION IN THE ECS(SPSB4)
RP   COMPLEX, IDENTIFICATION IN THE ECS(RAB40C) COMPLEX, IDENTIFICATION IN THE
RP   ECS(WSB1) COMPLEX, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION
RP   WITH LRRC41; SOCS3; SPSB1; SPSB2; SPSB4; WSB1 AND RAB40C.
RX   PubMed=15601820; DOI=10.1101/gad.1252404;
RA   Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C.,
RA   Conaway J.W., Nakayama K.I.;
RT   "VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1
RT   and Cul5-Rbx2 modules of ubiquitin ligases.";
RL   Genes Dev. 18:3055-3065(2004).
RN   [13]
RP   INTERACTION WITH ASB1; ASB2; ASB6; ASB7 AND ASB12.
RX   PubMed=16325183; DOI=10.1016/j.febslet.2005.11.016;
RA   Kohroki J., Nishiyama T., Nakamura T., Masuho Y.;
RT   "ASB proteins interact with cullin5 and Rbx2 to form E3 ubiquitin ligase
RT   complexes.";
RL   FEBS Lett. 579:6796-6802(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-210, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH ELOA; ELOB; ELOC AND RBX1.
RX   PubMed=19920177; DOI=10.1073/pnas.0907052106;
RA   Harreman M., Taschner M., Sigurdsson S., Anindya R., Reid J., Somesh B.,
RA   Kong S.E., Banks C.A., Conaway R.C., Conaway J.W., Svejstrup J.Q.;
RT   "Distinct ubiquitin ligases act sequentially for RNA polymerase II
RT   polyubiquitylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:20705-20710(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   INTERACTION WITH ASB2.
RX   PubMed=21119685; DOI=10.1038/cr.2010.165;
RA   Nie L., Zhao Y., Wu W., Yang Y.Z., Wang H.C., Sun X.H.;
RT   "Notch-induced Asb2 expression promotes protein ubiquitination by forming
RT   non-canonical E3 ligase complexes.";
RL   Cell Res. 21:754-769(2011).
RN   [18]
RP   INTERACTION WITH NOS2.
RX   PubMed=21199876; DOI=10.1074/jbc.m110.190678;
RA   Nishiya T., Matsumoto K., Maekawa S., Kajita E., Horinouchi T.,
RA   Fujimuro M., Ogasawara K., Uehara T., Miwa S.;
RT   "Regulation of inducible nitric-oxide synthase by the SPRY domain- and SOCS
RT   box-containing proteins.";
RL   J. Biol. Chem. 286:9009-9019(2011).
RN   [19]
RP   INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION).
RX   PubMed=21697472; DOI=10.1128/jvi.00733-11;
RA   Li X., Liang D., Lin X., Robertson E.S., Lan K.;
RT   "Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear
RT   antigen reduces interleukin-8 expression in endothelial cells and impairs
RT   neutrophil chemotaxis by degrading nuclear p65.";
RL   J. Virol. 85:8606-8615(2011).
RN   [20]
RP   INTERACTION WITH ARIH2, AND NEDDYLATION.
RX   PubMed=24076655; DOI=10.1038/emboj.2013.209;
RA   Kelsall I.R., Duda D.M., Olszewski J.L., Hofmann K., Knebel A.,
RA   Langevin F., Wood N., Wightman M., Schulman B.A., Alpi A.F.;
RT   "TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-
RT   RING ligase complexes.";
RL   EMBO J. 32:2848-2860(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INTERACTION WITH DCUN1D1; DCUN1D2; DCUN1D3; DCUN1D4 AND DCUN1D5.
RX   PubMed=23201271; DOI=10.1016/j.str.2012.10.013;
RA   Monda J.K., Scott D.C., Miller D.J., Lydeard J., King D., Harper J.W.,
RA   Bennett E.J., Schulman B.A.;
RT   "Structural conservation of distinctive N-terminal acetylation-dependent
RT   interactions across a family of mammalian NEDD8 ligation enzymes.";
RL   Structure 21:42-53(2013).
RN   [23]
RP   INTERACTION WITH MOLLUSCUM CONTAGIOSUM VIRUS PROTEIN MC132 (MICROBIAL
RP   INFECTION).
RX   PubMed=26041281; DOI=10.1128/jvi.00799-15;
RA   Brady G., Haas D.A., Farrell P.J., Pichlmair A., Bowie A.G.;
RT   "Poxvirus protein MC132 from molluscum contagiosum virus inhibits NF-B
RT   activation by targeting p65 for degradation.";
RL   J. Virol. 89:8406-8415(2015).
RN   [24]
RP   INTERACTION WITH DCUN1D1; DCUN1D2; DCUN1D3; DCUN1D4 AND DCUN1D5.
RX   PubMed=26906416; DOI=10.1242/jcs.181784;
RA   Keuss M.J., Thomas Y., Mcarthur R., Wood N.T., Knebel A., Kurz T.;
RT   "Characterization of the mammalian family of DCN-type NEDD8 E3 ligases.";
RL   J. Cell Sci. 129:1441-1454(2016).
RN   [25]
RP   INTERACTION WITH ERCC6 AND ELOA.
RX   PubMed=28292928; DOI=10.1074/jbc.c117.777946;
RA   Weems J.C., Slaughter B.D., Unruh J.R., Boeing S., Hall S.M., McLaird M.B.,
RA   Yasukawa T., Aso T., Svejstrup J.Q., Conaway J.W., Conaway R.C.;
RT   "Cockayne syndrome B protein regulates recruitment of the Elongin A
RT   ubiquitin ligase to sites of DNA damage.";
RL   J. Biol. Chem. 292:6431-6437(2017).
RN   [26]
RP   FUNCTION, PATHWAY, AND IDENTIFICATION IN A E3 UBIQUITIN-PROTEIN LIGASE
RP   COMPLEX CONTAINING KLHDC1.
RX   PubMed=32200094; DOI=10.1016/j.isci.2020.100970;
RA   Okumura F., Fujiki Y., Oki N., Osaki K., Nishikimi A., Fukui Y.,
RA   Nakatsukasa K., Kamura T.;
RT   "Cul5-type ubiquitin ligase KLHDC1 contributes to the elimination of
RT   truncated SELENOS produced by failed UGA/Sec decoding.";
RL   IScience 23:100970-100970(2020).
RN   [27]
RP   IDENTIFICATION IN A E3 UBIQUITIN-PROTEIN LIGASE COMPLEX CONTAINING PCMTD1.
RX   PubMed=35486881; DOI=10.1021/acs.biochem.2c00130;
RA   Warmack R.A., Pang E.Z., Peluso E., Lowenson J.D., Ong J.Y., Torres J.Z.,
RA   Clarke S.G.;
RT   "Human Protein-l-isoaspartate O-Methyltransferase Domain-Containing Protein
RT   1 (PCMTD1) Associates with Cullin-RING Ligase Proteins.";
RL   Biochemistry 61:879-894(2022).
RN   [28]
RP   SUBCELLULAR LOCATION.
RX   PubMed=35633597; DOI=10.1016/j.dnarep.2022.103343;
RA   Herlihy A.E., Boeing S., Weems J.C., Walker J., Dirac-Svejstrup A.B.,
RA   Lehner M.H., Conaway R.C., Conaway J.W., Svejstrup J.Q.;
RT   "UBAP2/UBAP2L regulate UV-induced ubiquitylation of RNA polymerase II and
RT   are the human orthologues of yeast Def1.";
RL   DNA Repair 115:103343-103343(2022).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 401-780 IN COMPLEX WITH NEDD8 AND
RP   RBX1, AND NEDDYLATION AT LYS-724.
RX   PubMed=18805092; DOI=10.1016/j.cell.2008.07.022;
RA   Duda D.M., Borg L.A., Scott D.C., Hunt H.W., Hammel M., Schulman B.A.;
RT   "Structural insights into NEDD8 activation of cullin-RING ligases:
RT   conformational control of conjugation.";
RL   Cell 134:995-1006(2008).
CC   -!- FUNCTION: Core component of multiple SCF-like ECS (Elongin-Cullin 2/5-
CC       SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate
CC       the ubiquitination and subsequent proteasomal degradation of target
CC       proteins (PubMed:11384984, PubMed:15601820). As a scaffold protein may
CC       contribute to catalysis through positioning of the substrate and the
CC       ubiquitin-conjugating enzyme (PubMed:11384984, PubMed:15601820). The
CC       functional specificity of the E3 ubiquitin-protein ligase complex
CC       depends on the variable substrate recognition component
CC       (PubMed:11384984, PubMed:15601820). ECS(SOCS1) seems to direct
CC       ubiquitination of JAK2 (PubMed:11384984). ECS(KLHDC1) complex is part
CC       of the DesCEND (destruction via C-end degrons) pathway and mediates
CC       ubiquitination and degradation of truncated SELENOS selenoprotein
CC       produced by failed UGA/Sec decoding, which ends with a glycine
CC       (PubMed:32200094). As part of a multisubunit complex composed of
CC       elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5;
CC       polyubiquitinates monoubiquitinated POLR2A (PubMed:19920177). May form
CC       a cell surface vasopressin receptor (PubMed:9037604).
CC       {ECO:0000269|PubMed:11384984, ECO:0000269|PubMed:15601820,
CC       ECO:0000269|PubMed:19920177, ECO:0000269|PubMed:32200094,
CC       ECO:0000269|PubMed:9037604}.
CC   -!- FUNCTION: (Microbial infection) Seems to be involved in proteasomal
CC       degradation of p53/TP53 stimulated by adenovirus E1B-55 kDa protein.
CC       {ECO:0000269|PubMed:12186903}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:11384984, ECO:0000269|PubMed:15601820,
CC       ECO:0000269|PubMed:32200094}.
CC   -!- SUBUNIT: Component of multiple ECS (Elongin BC-CUL2/5-SOCS-box protein)
CC       E3 ubiquitin-protein ligase complexes formed of CUL5, Elongin BC (ELOB
CC       and ELOC), RBX2 and a variable SOCS box domain-containing protein as
CC       substrate-specific recognition component (PubMed:11384984,
CC       PubMed:15601820). Component of the probable ECS(LRRC41) complex with
CC       the substrate recognition component LRRC41 (PubMed:11384984). Component
CC       of the probable ECS(SOCS1) complex with the substrate recognition
CC       component SOCS1 (PubMed:11384984). Component of the probable ECS(WSB1)
CC       complex with the substrate recognition subunit WSB1 (PubMed:15601820).
CC       Component of the probable ECS(SOCS3) complex with the substrate
CC       recognition component SOCS3 (PubMed:15601820). Component of the
CC       probable ECS(SPSB1) complex with the substrate recognition component
CC       SPSB1 (PubMed:15601820). Component of the probable ECS(SPSB2) complex
CC       with the substrate recognition component SPSB2 (PubMed:15601820).
CC       Component of the probable ECS(SPSB4) complex with the substrate
CC       recognition component SPSB4 (PubMed:15601820). Component of the
CC       probable ECS(RAB40C) complex with the substrate recognition subunit
CC       RAB40C (PubMed:15601820). Component of the probable ECS(KLHDC1) complex
CC       with the substrate recognition component KLHDC1 (PubMed:32200094). May
CC       also form complexes containing CUL5, elongin BC complex (ELOB and
CC       ELOC), RBX1 and ELOA (PubMed:11384984, PubMed:19920177). May also form
CC       complexes containing CUL5, Elongin BC (ELOB and ELOC), RBX1 and VHL
CC       (PubMed:10230407, PubMed:18805092). Interacts with RNF7/RBX2, LRRC41,
CC       SOCS3, SPSB1, SPSB2, SPSB4 and RAB40C (PubMed:15601820). Interacts with
CC       ASB1, ASB2, ASB6, ASB7 and ASB12 (PubMed:16325183, PubMed:21119685).
CC       Interacts (when neddylated) with ARIH2; leading to activate the E3
CC       ligase activity of ARIH1 (PubMed:24076655). Interacts with NOS2 in the
CC       presence of SPSB1 or SPSB2 or SPSB4 (PubMed:21199876). Interacts with
CC       ERCC6; the interaction is induced by DNA damaging agents or inhibitors
CC       of RNA polymerase II elongation (PubMed:28292928). Interacts with ELOA
CC       (via the BC-box) (PubMed:28292928). Interacts (unneddylated form) with
CC       DCUN1D1, DCUN1D2, DCUN1D3, DCUN1D4 and DCUN1D5; these interactions
CC       promote the cullin neddylation (PubMed:23201271, PubMed:26906416).
CC       Component of the probable ECS(PCMTD1) complex with the substrate
CC       recognition subunit PCMTD1 (PubMed:35486881).
CC       {ECO:0000269|PubMed:10230407, ECO:0000269|PubMed:11384984,
CC       ECO:0000269|PubMed:15601820, ECO:0000269|PubMed:16325183,
CC       ECO:0000269|PubMed:18805092, ECO:0000269|PubMed:19920177,
CC       ECO:0000269|PubMed:21199876, ECO:0000269|PubMed:23201271,
CC       ECO:0000269|PubMed:24076655, ECO:0000269|PubMed:26906416,
CC       ECO:0000269|PubMed:28292928, ECO:0000269|PubMed:32200094,
CC       ECO:0000269|PubMed:35486881}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via the substrate recognition
CC       component) with HIV-1 Vif. {ECO:0000269|PubMed:12186903}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via the substrate recognition
CC       component) with human adenovirus 5 proteins E1B-55K and E4-orf6.
CC       {ECO:0000269|PubMed:12186903}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein
CC       LANA1; this interaction promotes the degradation of NF-kappa-B
CC       component RELA. {ECO:0000269|PubMed:21697472}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with molluscum contagiosum
CC       virus protein MC132; this interaction promotes the degradation of NF-
CC       kappa-B component RELA. {ECO:0000269|PubMed:26041281}.
CC   -!- INTERACTION:
CC       Q93034; O95376: ARIH2; NbExp=12; IntAct=EBI-1057139, EBI-711158;
CC       Q93034; Q9Y576: ASB1; NbExp=6; IntAct=EBI-1057139, EBI-2323092;
CC       Q93034; Q96Q27-2: ASB2; NbExp=3; IntAct=EBI-1057139, EBI-28950233;
CC       Q93034; Q9NWX5: ASB6; NbExp=9; IntAct=EBI-1057139, EBI-6425205;
CC       Q93034; Q9H672: ASB7; NbExp=3; IntAct=EBI-1057139, EBI-3916346;
CC       Q93034; Q9NPC3: CCNB1IP1; NbExp=3; IntAct=EBI-1057139, EBI-745269;
CC       Q93034; O95273: CCNDBP1; NbExp=4; IntAct=EBI-1057139, EBI-748961;
CC       Q93034; Q9Y2V7: COG6; NbExp=3; IntAct=EBI-1057139, EBI-3866319;
CC       Q93034; P04626: ERBB2; NbExp=2; IntAct=EBI-1057139, EBI-641062;
CC       Q93034; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1057139, EBI-618309;
CC       Q93034; P42858: HTT; NbExp=10; IntAct=EBI-1057139, EBI-466029;
CC       Q93034; Q5T7N3: KANK4; NbExp=3; IntAct=EBI-1057139, EBI-9355810;
CC       Q93034; P62877: RBX1; NbExp=3; IntAct=EBI-1057139, EBI-398523;
CC       Q93034; Q9UBF6: RNF7; NbExp=8; IntAct=EBI-1057139, EBI-398632;
CC       Q93034; O14508: SOCS2; NbExp=9; IntAct=EBI-1057139, EBI-617737;
CC       Q93034; O41974: GAMMAHV.ORF73; Xeno; NbExp=2; IntAct=EBI-1057139, EBI-6933128;
CC       Q93034; P12504: vif; Xeno; NbExp=11; IntAct=EBI-1057139, EBI-779991;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:35633597}.
CC       Note=Localizes to sites of DNA damage in a UBAP2 and UBAP2L-dependent
CC       manner. {ECO:0000269|PubMed:35633597}.
CC   -!- PTM: Neddylated; which enhances the ubiquitination activity of SCF and
CC       prevents binding of the inhibitor CAND1. Deneddylated via its
CC       interaction with the COP9 signalosome (CSN).
CC       {ECO:0000269|PubMed:10597293, ECO:0000269|PubMed:12186903,
CC       ECO:0000269|PubMed:18805092, ECO:0000269|PubMed:24076655}.
CC   -!- SIMILARITY: Belongs to the cullin family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00330}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X81882; CAA57465.1; -; mRNA.
DR   EMBL; AF017061; AAB70253.1; -; mRNA.
DR   EMBL; AF327710; AAK07472.1; -; mRNA.
DR   EMBL; AK292575; BAF85264.1; -; mRNA.
DR   EMBL; CH471065; EAW67102.1; -; Genomic_DNA.
DR   EMBL; BC063306; AAH63306.1; -; mRNA.
DR   CCDS; CCDS31668.1; -.
DR   RefSeq; NP_003469.2; NM_003478.4.
DR   PDB; 3DPL; X-ray; 2.60 A; C=401-780.
DR   PDB; 3DQV; X-ray; 3.00 A; C/D=401-780.
DR   PDB; 4JGH; X-ray; 3.00 A; D=10-386.
DR   PDB; 4N9F; X-ray; 3.30 A; 3/9/C/I/O/U/V/f/l/r/w/x=12-321.
DR   PDB; 6V9I; EM; 5.20 A; C=2-780.
DR   PDB; 7ONI; EM; 3.40 A; C=1-780.
DR   PDBsum; 3DPL; -.
DR   PDBsum; 3DQV; -.
DR   PDBsum; 4JGH; -.
DR   PDBsum; 4N9F; -.
DR   PDBsum; 6V9I; -.
DR   PDBsum; 7ONI; -.
DR   AlphaFoldDB; Q93034; -.
DR   SMR; Q93034; -.
DR   BioGRID; 113743; 550.
DR   CORUM; Q93034; -.
DR   DIP; DIP-43696N; -.
DR   IntAct; Q93034; 373.
DR   MINT; Q93034; -.
DR   STRING; 9606.ENSP00000376808; -.
DR   GlyGen; Q93034; 1 site, 2 O-linked glycans (1 site).
DR   iPTMnet; Q93034; -.
DR   PhosphoSitePlus; Q93034; -.
DR   BioMuta; CUL5; -.
DR   DMDM; 14917099; -.
DR   EPD; Q93034; -.
DR   jPOST; Q93034; -.
DR   MassIVE; Q93034; -.
DR   MaxQB; Q93034; -.
DR   PaxDb; Q93034; -.
DR   PeptideAtlas; Q93034; -.
DR   ProteomicsDB; 75673; -.
DR   Antibodypedia; 990; 258 antibodies from 36 providers.
DR   DNASU; 8065; -.
DR   Ensembl; ENST00000393094.7; ENSP00000376808.2; ENSG00000166266.14.
DR   Ensembl; ENST00000531427.5; ENSP00000435376.1; ENSG00000166266.14.
DR   GeneID; 8065; -.
DR   KEGG; hsa:8065; -.
DR   MANE-Select; ENST00000393094.7; ENSP00000376808.2; NM_003478.6; NP_003469.2.
DR   UCSC; uc001pjv.4; human.
DR   AGR; HGNC:2556; -.
DR   CTD; 8065; -.
DR   DisGeNET; 8065; -.
DR   GeneCards; CUL5; -.
DR   HGNC; HGNC:2556; CUL5.
DR   HPA; ENSG00000166266; Low tissue specificity.
DR   MIM; 601741; gene.
DR   neXtProt; NX_Q93034; -.
DR   OpenTargets; ENSG00000166266; -.
DR   PharmGKB; PA27052; -.
DR   VEuPathDB; HostDB:ENSG00000166266; -.
DR   eggNOG; KOG2285; Eukaryota.
DR   GeneTree; ENSGT00940000156648; -.
DR   HOGENOM; CLU_004747_5_0_1; -.
DR   InParanoid; Q93034; -.
DR   OMA; YRENFEA; -.
DR   OrthoDB; 5474206at2759; -.
DR   PhylomeDB; Q93034; -.
DR   TreeFam; TF105874; -.
DR   PathwayCommons; Q93034; -.
DR   Reactome; R-HSA-180585; Vif-mediated degradation of APOBEC3G.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-9705462; Inactivation of CSF3 (G-CSF) signaling.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q93034; -.
DR   SIGNOR; Q93034; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 8065; 48 hits in 1213 CRISPR screens.
DR   ChiTaRS; CUL5; human.
DR   EvolutionaryTrace; Q93034; -.
DR   GeneWiki; CUL5; -.
DR   GenomeRNAi; 8065; -.
DR   Pharos; Q93034; Tbio.
DR   PRO; PR:Q93034; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q93034; protein.
DR   Bgee; ENSG00000166266; Expressed in secondary oocyte and 219 other tissues.
DR   ExpressionAtlas; Q93034; baseline and differential.
DR   Genevisible; Q93034; HS.
DR   GO; GO:0031466; C:Cul5-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019005; C:SCF ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB.
DR   GO; GO:0005262; F:calcium channel activity; TAS:ProtInc.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IBA:GO_Central.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:Reactome.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:ProtInc.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0016567; P:protein ubiquitination; IBA:GO_Central.
DR   GO; GO:0031146; P:SCF-dependent proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   Gene3D; 1.20.1310.10; Cullin Repeats; 4.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1.
DR   IDEAL; IID00519; -.
DR   InterPro; IPR045093; Cullin.
DR   InterPro; IPR016157; Cullin_CS.
DR   InterPro; IPR016158; Cullin_homology.
DR   InterPro; IPR036317; Cullin_homology_sf.
DR   InterPro; IPR001373; Cullin_N.
DR   InterPro; IPR019559; Cullin_neddylation_domain.
DR   InterPro; IPR016159; Cullin_repeat-like_dom_sf.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11932; CULLIN; 1.
DR   PANTHER; PTHR11932:SF76; CULLIN-5; 1.
DR   Pfam; PF00888; Cullin; 1.
DR   Pfam; PF10557; Cullin_Nedd8; 1.
DR   SMART; SM00182; CULLIN; 1.
DR   SMART; SM00884; Cullin_Nedd8; 1.
DR   SUPFAM; SSF75632; Cullin homology domain; 1.
DR   SUPFAM; SSF74788; Cullin repeat-like; 1.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1.
DR   PROSITE; PS01256; CULLIN_1; 1.
DR   PROSITE; PS50069; CULLIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Host-virus interaction; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Receptor; Reference proteome; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN           1..780
FT                   /note="Cullin-5"
FT                   /id="PRO_0000119797"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         210
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CROSSLNK        724
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in NEDD8)"
FT                   /evidence="ECO:0000269|PubMed:18805092"
FT   CONFLICT        9
FT                   /note="N -> D (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        12
FT                   /note="S -> F (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        16
FT                   /note="E -> G (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        32..34
FT                   /note="QES -> RDF (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        38
FT                   /note="Q -> R (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        50..52
FT                   /note="VCL -> FCF (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        68
FT                   /note="D -> DF (in Ref. 2; AAB70253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        224
FT                   /note="Q -> P (in Ref. 1; CAA57465)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        648
FT                   /note="L -> F (in Ref. 1; CAA57465)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        651
FT                   /note="E -> D (in Ref. 1; CAA57465)"
FT                   /evidence="ECO:0000305"
FT   HELIX           15..30
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           37..53
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           57..81
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           86..103
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   TURN            104..108
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           112..115
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           134..146
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           148..167
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           175..186
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           196..199
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           202..224
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           227..248
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           257..269
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           271..273
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           278..280
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           281..286
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           290..300
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   TURN            304..306
FT                   /evidence="ECO:0007829|PDB:4N9F"
FT   HELIX           310..333
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           337..357
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   TURN            358..361
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           363..377
FT                   /evidence="ECO:0007829|PDB:4JGH"
FT   HELIX           405..416
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          417..419
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           420..423
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           427..438
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           439..443
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           447..463
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           470..482
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           487..513
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           523..525
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          526..532
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           533..536
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           549..552
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           555..563
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          566..573
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           575..577
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          579..585
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          590..596
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           597..603
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           604..606
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          607..609
FT                   /evidence="ECO:0007829|PDB:7ONI"
FT   HELIX           616..623
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           627..638
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          647..652
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           657..659
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          665..668
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          674..687
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   TURN            690..693
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           697..723
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          726..729
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           731..741
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   TURN            742..745
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   HELIX           750..762
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          765..769
FT                   /evidence="ECO:0007829|PDB:3DPL"
FT   STRAND          772..778
FT                   /evidence="ECO:0007829|PDB:3DPL"
SQ   SEQUENCE   780 AA;  90955 MW;  57463CB4ED76E303 CRC64;
     MATSNLLKNK GSLQFEDKWD FMRPIVLKLL RQESVTKQQW FDLFSDVHAV CLWDDKGPAK
     IHQALKEDIL EFIKQAQARV LSHQDDTALL KAYIVEWRKF FTQCDILPKP FCQLEITLMG
     KQGSNKKSNV EDSIVRKLML DTWNESIFSN IKNRLQDSAM KLVHAERLGE AFDSQLVIGV
     RESYVNLCSN PEDKLQIYRD NFEKAYLDST ERFYRTQAPS YLQQNGVQNY MKYADAKLKE
     EEKRALRYLE TRRECNSVEA LMECCVNALV TSFKETILAE CQGMIKRNET EKLHLMFSLM
     DKVPNGIEPM LKDLEEHIIS AGLADMVAAA ETITTDSEKY VEQLLTLFNR FSKLVKEAFQ
     DDPRFLTARD KAYKAVVNDA TIFKLELPLK QKGVGLKTQP ESKCPELLAN YCDMLLRKTP
     LSKKLTSEEI EAKLKEVLLV LKYVQNKDVF MRYHKAHLTR RLILDISADS EIEENMVEWL
     REVGMPADYV NKLARMFQDI KVSEDLNQAF KEMHKNNKLA LPADSVNIKI LNAGAWSRSS
     EKVFVSLPTE LEDLIPEVEE FYKKNHSGRK LHWHHLMSNG IITFKNEVGQ YDLEVTTFQL
     AVLFAWNQRP REKISFENLK LATELPDAEL RRTLWSLVAF PKLKRQVLLY EPQVNSPKDF
     TEGTLFSVNQ EFSLIKNAKV QKRGKINLIG RLQLTTERMR EEENEGIVQL RILRTQEAII
     QIMKMRKKIS NAQLQTELVE ILKNMFLPQK KMIKEQIEWL IEHKYIRRDE SDINTFIYMA
//
